Scynexis Soars 11.23% as MARIO Study Resumes

On May 29, 2025, Scynexis saw a significant pre-market rise of 11.23%, driven by the resumption of patient dosing in its Phase 3 MARIO study.

Scynexis has resumed patient dosing in its Phase 3 MARIO study, which investigates oral ibrexafungerp as a potential step-down antifungal therapy for invasive candidiasis. The study had been on hold due to concerns about potential cross-contamination, but has now resumed following the manufacture of new clinical supplies at another site and the lifting of the clinical hold by the FDA. The resumption of dosing triggers a $10 million milestone payment from partner GSK, with another $20 million payment due in six months. However, there is a disagreement between Scynexis and GSK regarding these milestone payments.

Scynexis is developing innovative medicines to help patients overcome and prevent difficult-to-treat infections. The company's proprietary antifungal platform, "fungerps," includes ibrexafungerp, which has been approved for the treatment of vulvovaginal candidiasis and is in late-stage development for invasive candidiasis. The resumption of the MARIO study is a significant step forward in the development of new treatment options for life-threatening fungal infections.